Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Social and Behavioral Sciences

PDF

Faculty of Science, Medicine and Health - Papers: part A

2012

Disease

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

Understanding And Benchmarking Health Service Achievement Of Policy Goals For Chronic Disease, Erica Bell, Bastian Seidel Jan 2012

Understanding And Benchmarking Health Service Achievement Of Policy Goals For Chronic Disease, Erica Bell, Bastian Seidel

Faculty of Science, Medicine and Health - Papers: part A

Background Key challenges in benchmarking health service achievement of policy goals in areas such as chronic disease are: 1) developing indicators and understanding how policy goals might work as indicators of service performance; 2) developing methods for economically collecting and reporting stakeholder perceptions; 3) combining and sharing data about the performance of organizations; 4) interpreting outcome measures; 5) obtaining actionable benchmarking information. This study aimed to explore how a new Boolean-based small-N method from the social sciences—Qualitative Comparative Analysis or QCA—could contribute to meeting these internationally shared challenges. Methods A ‘multi-value QCA’ (MVQCA) analysis was conducted of data from 24 …


Is Seladin-1 Really A Selective Alzheimer's Disease Indicator?, Laura J. Sharpe, Jenny Wong, Brett Garner, Glenda M. Halliday, Andrew J. Brown Jan 2012

Is Seladin-1 Really A Selective Alzheimer's Disease Indicator?, Laura J. Sharpe, Jenny Wong, Brett Garner, Glenda M. Halliday, Andrew J. Brown

Faculty of Science, Medicine and Health - Papers: part A

Selective Alzheimer's Disease Indicator-1 (Seladin-1) was originally identified by its down-regulation in the brains of Alzheimer's disease (AD) patients. Here, we re-examine existing data and present new gene expression data that refutes its role as a selective AD indicator. Furthermore, we caution against the use of the name “Seladin-1” and instead recommend adoption of the approved nomenclature, 3β-hydroxysterol Δ24-reductase (or DHCR24), which describes its catalytic function in cholesterol synthesis. Further work is required to determine what link, if any, exists between DHCR24 and AD.